dr. richard klausner, director of grail, a company developing a blood test for cancer, known as a liquid biopsy. >> somebody with no symptoms could get their blood drawn? >> exactly. >> reporter: you could determine if they have cancer. >> the holy grail. >> reporter: the idea hold great klausner says proving it works will take time. >> the answers are not going to be clear until we do definitive and large scale studies because we need to know, not that this sound good, but that it is true. >> reporter: any company saying that time is now? >> we just don't have the clinical data yet. we have to get it. >> reporter: there is a lot of incentive, the liquid biopsy market is expected to be worth $22 billion by 2020. another company after a piece of it, san diego based pathway genomics. pathway's roster of board members includes former chair of the joint chiefs of staff, peter pace, former secretary of commerce, barbara franklin and newt gingrich. pathway raised $40 million in its the last round of fund-raising. >> like the most amazing thing. >> reporter: and raised its profile on an episode

dr. richard klausner, director of grail, a company developing a blood test for cancer, known as a liquid biopsy. >> somebody with no symptoms could get their blood drawn? >> exactly. >> reporter: you could determine >> the holy grail. >> reporter: the idea hold great promise. klausner says proving it works will take time. >> we don't hatch the clinical data yet. we have to get it. incentive, the liquid biopsy market is expected to beep worth $22 billion by 2020. another company after a piece of it, san diego based pathway genomics. pathway raised $40 million in its last round of fund-raising. ed raised its profiles when one genetic test was featured on "keeping up with the kardashians." >> mitch mulinex. >> reporter: what caught our attention, the test launched in december. cancer intercept detect and monitor. >> reporter: available by physician order for as little as $299, pathway's marketing claimed it could do what others say is years away. growing tumor in the bed before ody. >> a few weeks ago we visited pathway to ask them about their claims. before we sat down with the ceo, jim pl

dr. richard klausner, director of grail, a company developing a blood test for cancer, known as a liquid biopsy. >> somebody with no symptoms could get their blood drawn? >> exactly. >> reporter: you could determine if they have cancer. >> the holy grail. >> reporter: the idea hold great promise. klausner says proving it works will take time. >> we just don't have the clinical data yet. we have to get it. >> reporter: there is a lot of incentive, the liquid biopsy market is expected to be worth $22 billion by 2020. another company after a piece of it, san diego based pathway genomics. pathway raised $40 million in its last round of fund-raising. >> like the most amazing thing. >> reporter: and raised its profiles when one genetic test was featured on "keeping up with the kardashians." >> hi, how are you. >> mitch mulinex. with pathway genomics. nice to meet you. >> reporter: what caught our attention, the test launched in >> introducing pathway genomics revolutionary test cancer intercept detect and monitor. >> reporter: available by physician order for as little as $299, pathway's marke

dr. richard klausner is the former head of the national cancer institute and a director of grail, a company dwrepg a blood fest interest cancer known as a symptoms. >> no symptoms. >> reporter: could get their blood drawn. >> exactly. >> reporter:and you could determine they have cancer. >> that's the holy grail. >> reporter: the idea holds great promise, but klausner says proving it works will take time. >> we just don't have the clipical data and the yt and we have to get it. >> reporter: there is a lot of incentive. the liquid biopsy market is expected to be worth $22 billion by 2020. liquid biopsy will detect cancer before symptoms. >> may, may. >> reporter: that's not what the video says. >> it says may. we don't way "will." we say may. >> reporter: you don't make the claim that you can detect cancer? >> we say the information can be used to help guide potential early-- early diagnosis. >> reporter: we also asked plante about this chart showing the advantages of their liquid biopsy over a traditional tissue biopsy. >> we never say it replaces solid tissue biopsy. >> reporter: this char

dr. richard klausner is the former head of the national cancer institute and a director of grail, a interest cancer known as a liquid biopsy somebody with no symptoms. >> no symptoms. blood drawn. >> exactly. >> reporter:and you could determine they have cancer. >> that's the holy grail. >> reporter: the idea holds great promise, but klausner says proving it works will take time. >> we just don't have the clipical data and the yt and we have to get it. >> reporter: there is a lot of incentive. the liquid biopsy market is expected to be worth $22 billion by 2020. another company after a piece of it is san diego-based pathway genomics. pathway raised $40 million in its last round of fund-raising. >> it's, like, the most amazing thing. >> reporter: and raised its profile when one of its genetic tests was featured on "keeping up with the kardashians." >> mitch mulinex from pathway genomics. >> nice to see you. >> reporter: what caughture attention was the test pathway launched in september. >> introducing pathway genomics' revolutionary test-- cancer intercept, detect and monitor. physician orde

dr. richard klausner is the former head of and a director of grail, a company developing a blood test st c for cancer known as a liquid biopsy somebody with no symptoms. >> no symptoms. >> reporter: could get their blood drawn. >> exactly. ms >> reporter: and you could determine they have cancer. y. >> that's the holy grail. ha >> reporter: the idea holds great promise, but klausner says in >> we just don't have the clinical data yet and we have to get it. >> reporter: there is a lot of incentive. the liquid biopsy market is expected to be worth $22 billion by 2020. another company after a piece of it is san diego-based pathway genomics. pathway raised $40 million in nd >> it's, like, the most amazing thing. >> reporter: and raised its profile when one of its genetic tests was featured on "keeping up with the kardashians." >> mitch mulinex from pathway keep genomics. >> nice to see you. >> reporter: what caught the attention was the test pathway launched in september. revolutionary test-- cancer intercept, detect and monitor. >> reporter: available by physician order for as little as $29

dr. richard klausner is the director of grail, a company developing a blood test for detecting cancer. known as a blood biopsy. >> you could determine if they have cancer. >> that's the holy grail. >> the idea is a great but proving it will take time. >> the answers are not going to be clear until we do definitive and large-scale studies because we need to know not if it sounds good but if it's true. >> is any company saying that that time is now? >> we just don't have the >> there's a lot of incentive. the liquid biopsy market is expected to be worth $22 billion by 20. another company after a piece of it is san diego-based pathway jeno gentlemen genomics. it includes peter pace, barbara franklin and newt gingrich. pathway rads $40 million in its last fund-raising and raised their profile in an episode of keeping up with the kardashians. >> hi. >> nice to meet you. >> what caught our attention is the test pathway launched last december. >> cancer, intercept deerks text, and monitor. >> reporter: available for $299 pathway's marketing claims it years away. >> cancer intercept can detect

dr. richard klausner is the former head of the national cancer institute and a director of grail, a company developing a blood test for cancer, known as a liquid biopsy.(axe 10;32;33;08) someone with no symptoms...(klausener) no symptoms (axe) could get their blood drawn(klausner 10;32;37;28) exactly. (axe 10;32;37;28) you could // determine they have cancer? (klausner) that is the holy grail.narr: the idea holds great promise, but klausner says proving it works will take time. (klausner) the answers are not going to be clear we do definitive and large scale studies because we need to know, not that this sounds good // but that it's true.(axelrod) and any company saying that that time is now, in your view?(klausner) we just don't have the clinical data yet, and we have to get it. narr: (gfx) there is a lot of incentive: the liquid biopsy market is estimated to be worth $22 billion dollars by 2020. (gfx) another company after a piece of it is san diego-based pathway genomics (nat: pathway ringing the nasdaq bell) narr: (gfx) pathway's of board members include the of the joint chiefs of staff